Phase 3 N=326 Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
Pseudobulbar Affect (PBA)
Primary: PBA Episode Rate Ratio (Post/Pre), Regression Adjusted — 0.247; 0.237; 0.465 Unit-free (ratio of episodes/week) — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=367 Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
Pseudobulbar Affect (PBA) · Stroke · Dementia
Primary: Mean Change From Baseline in Center for Neurologic Study-Lability Scale (CNS-LS) Score at Day 90 — -7.69; -7.22; -7.59; -8.54 Units on a scale — p=<0.0001
Phase 2 N=28 Impact of Nuedexta on Bulbar Physiology and Function in ALS
Amyotrophic Lateral Sclerosis
Primary: Change in Dynamic Imaging Grade of Swallowing Toxicity — 3; 7 Participants — p=0.08
Phase 2 N=60 Clinical Trial Nuedexta in Subjects With ALS
Amyotrophic Lateral Sclerosis (ALS)
Primary: Bulbar Function Scale (CNS-BFS) Total Score — 53.45; 59.31 units on a scale — p=0.0003
Phase 2 N=13 Nuedexta for the Treatment of Adults With Autism
Autism
Primary: Change in Maladaptive Behaviors — -6.62; -1.08 units on a scale
N/A N=8 CB3 Pilot (Communication Bridge: A Person-centered Internet-based Intervention for Individuals With Primary Progressive Aphasia)
Aphasia · Primary Progressive Aphasia · Dementia
Primary: Change in Communication Confidence (CCRSA) — 64.32; 65.91; 63.00; 64.77 score on a scale
N/A N=17 The Emotion Builder: An Intervention for Emotional Deficits After Brain Injury
Traumatic Brain Injury · Alexithymia
Primary: Toronto Alexithymia Scale-20 (TAS-20) — 52.54 units on a scale
N/A N=8 Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy
Primary Progressive Aphasia · PPA
Primary: Change in Accuracy of Naming Trained Verbs (0 to 15, Higher Scores Reflect Better Naming Abilities) as Assessed by Object and Action Naming Battery (OANB) — 2.3; 2.05…
Phase 2 N=42 Masked Faces in Parkinson Disease: Mechanism and Treatment
Parkinson's Disease
Primary: Change in Facial Entropy Score From Baseline [Off Dopamine Medication] — 5.649; -1.605 units on a scale — p=< 0.001
N/A N=28 Neurobehavioral Intervention as a Novel Treatment Approach for Emotion-Regulatory Deficits
Anxiety · Depression
Primary: Reaction Time to Facial Affect Identification During Emotional Conflict — 802.15; 889.14; 848.79; 937.97 milliseconds — p=0.004
Phase 2 N=168 Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury
Neurobehavioral Disinhibition
Primary: Stage 1: Change From Baseline in the Composite of the Clinical Impression Severity Scores on the Neuropsychiatric Inventory Clinician Rating Scale (NPI-C) Subscale of…
N/A N=95 Positive Affect as a Source of Resilience for Adults in Chronic Pain
Geriatric · Chronic Pain
Primary: Recruitment as Measured by Rates of Enrollment (Aim 1) — 120; 95; 22; 2 Participants
N/A N=50 Valproate for Mood Swings and Alcohol Use Following Head Injury
Traumatic Brain Injury (TBI) · Alcoholism
Primary: Severity of Affective Lability Based on Shortened Agitated Behavior Scale — 9.22; 9.39 units on a scale
N/A N=10 TMS for the Treatment of Primary Progressive Aphasia
Logopenic Variant Primary Progressive Aphasia · Non-fluent Variant Primary Progressive Aphasia · Semantic Variant Primary Progressive Aphasia
Primary: Changes in Language as Measured Through the Boston Naming Test (BNT) — 1.8; 2.5; 0.063; 0.5 Items
N/A N=37 tDCS Intervention in Primary Progressive Aphasia
Primary Progressive Aphasia · MCI · FTD
Primary: Absolute Percent Change in Written Naming (Trained Items) — 39.4; 28.4; 33.1; 20.0 absolute percent change
Phase 2 N=119 Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)
Primary Biliary Cirrhosis
Primary: Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 8 — -26.06; -33.38; -41.42 percentage change from baseline — p== 0.2242
Phase 2 N=54 A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients
Drooling
Primary: Change in Drooling Frequency & Severity Scale (DFSS)at Wk 4 Post-injection — -2.1; -3.3; -3.5; -1.3 points on a scale
Phase 2 N=80 Brexpiprazole in Borderline Personality Disorder
Borderline Personality Disorder
Primary: Zanarini Rating Scale for Borderline Personality Disorder — 14.9; 14.9; 7.6; 6.7 score on a scale
Phase 3 N=187 Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
Sialorrhea
Primary: Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A) — -0.37; -0.36; -0.07 g/minute — p=<0.0001
N/A N=13 A P300 Brain Computer Interface Keyboard to Control Assistive Technology For Use by People With Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: Accuracy of Typing With a BCI Keyboard by ALS Patients. — 81; 78; 75 percentage accuracy